0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Reducing Opioid Abuse and Diversion

Perry G. Fine, MD; Scott M. Fishman, MD
JAMA. 2011;306(4):381-383. doi:10.1001/jama.2011.1042.
Text Size: A A A
Published online

Extract

To the Editor: Drs Volkow and McLellan1 recognize that it is by well-crafted, multifaceted public health approaches involving prescribers and the public that prescription opioid–related morbidity and mortality can be curtailed while preserving access to medically indicated opioid therapy. They point to important aspects of assessment and ongoing monitoring in risk management, including the use of urine drug testing. We are concerned that while overall costs of care and potential benefits of routine urine drug testing are being established,2 the coverage determination language of the Centers for Medicare & Medicaid Services and their contracted fiscal intermediaries does not support these contemporary principles of practice. For example, Medicare requires a suspicion of illicit drug use before covering routine preventive toxicology screens.3 This stands in contradiction to the position of Volkow and McLellan.1

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

July 27, 2011
Nora D. Volkow, MD; Thomas A. McLellan, PhD
JAMA. 2011;306(4):381-383. doi:10.1001/jama.2011.1043.
July 27, 2005
David R. Gastfriend, MD
JAMA. 2005;294(4):426-427. doi:10.1001/jama.294.4.427-a.
July 27, 2005
Sally Satel, MD
JAMA. 2005;294(4):426-427. doi:10.1001/jama.294.4.426-b.
July 27, 2011
Stella Fitzgibbons, MD
JAMA. 2011;306(4):381-383. doi:10.1001/jama.2011.1040.
July 27, 2011
Steven M. Marcus, MD
JAMA. 2011;306(4):381-383. doi:10.1001/jama.2011.1041.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();